JNJ

190.6

-0.77%↓

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

HQY

96.46

+0.12%↑

JNJ

190.6

-0.77%↓

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

HQY

96.46

+0.12%↑

JNJ

190.6

-0.77%↓

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

HQY

96.46

+0.12%↑

JNJ

190.6

-0.77%↓

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

HQY

96.46

+0.12%↑

JNJ

190.6

-0.77%↓

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

HQY

96.46

+0.12%↑

Search

Abbott Laboratories

Uždarymo kaina

SektoriusSveikatos priežiūra

126.77 0.33

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

125

Max

128.07

Pagrindiniai rodikliai

By Trading Economics

Pajamos

454M

1.8B

Pardavimai

227M

11B

P/E

Sektoriaus vid.

16.128

37.461

Pelnas, tenkantis vienai akcijai

1.3

Dividendų pajamingumas

1.84

Pelno marža

15.967

Darbuotojai

114,000

EBITDA

-824M

2.2B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+16.46% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.84%

2.33%

Kitas dividendų mokėjimo data

2025-11-17

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-3.3B

225B

Ankstesnė atidarymo kaina

126.44

Ankstesnė uždarymo kaina

126.77

Naujienos nuotaikos

By Acuity

40%

60%

114 / 371 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Abbott Laboratories Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-15 12:02; UTC

Uždarbis

Abbott Labs Posts Higher 3Q Sales, Reaffirms Outlook

2025-07-17 12:10; UTC

Uždarbis

Abbott Labs Pares Outlook, Logs 2Q Profit Gains

2025-10-22 19:57; UTC

Įsigijimai, susijungimai, perėmimai

Synlait Milk Ltd.: OIO Gives Abbott Consent to Acquire Co's North Island Assets

2025-10-15 16:15; UTC

Uždarbis

Abbott Stock Drops Despite Earnings. Baby-Formula Sales Took a Hit. -- Barrons.com

2025-10-15 12:25; UTC

Uždarbis

Abbott Posts Solid Earnings, Adult Nutrition Drives Sales. The Stock Drops Anyway. -- Barrons.com

2025-10-15 11:32; UTC

Uždarbis

Abbott Labs Still Sees 2025 Organic Sales Up 6%-7% Including Covid-19 Testing-Related Sales >ABT

2025-10-15 11:32; UTC

Uždarbis

Abbott Labs Still Sees 2025 Organic Sales Up 7.5%-8% Excluding Covid-19 Testing-Related Sales >ABT

2025-10-15 11:31; UTC

Uždarbis

Abbott Labs Sees 2025 Adj EPS $5.12-Adj EPS $5.18 >ABT

2025-10-15 11:30; UTC

Uždarbis

Abbott Labs 3Q Adjusted Operating Margin 23% >ABT

2025-10-15 11:30; UTC

Uždarbis

Abbott Labs Reaffirms Full-Year Guidance >ABT

2025-10-15 11:30; UTC

Uždarbis

Abbott Labs 3Q Organic Sales Growth Up 5.5% >ABT

2025-10-15 11:30; UTC

Uždarbis

Abbott Labs 3Q Sales $11.37B >ABT

2025-10-15 11:30; UTC

Uždarbis

Abbott Labs 3Q Adj EPS $1.30 >ABT

2025-10-15 11:30; UTC

Uždarbis

Abbott Labs 3Q Net $1.64B >ABT

2025-10-15 11:30; UTC

Uždarbis

Abbott Labs 3Q EPS 94c >ABT

2025-10-11 00:18; UTC

Įsigijimai, susijungimai, perėmimai

Why Biotech May Be Back -- Barrons.com

2025-07-17 13:14; UTC

Uždarbis

Abbott Labs Stock Falls After Earnings. Why Rising Sales Fail to Lift Shares. -- Barrons.com

2025-07-17 12:16; UTC

Uždarbis

Abbott Labs Stock Dives After Earnings Miss. Why Rising Sales Fail to Lift Shares. -- Barrons.com

2025-07-17 11:32; UTC

Uždarbis

Abbott Labs Sees 3Q Adj EPS $1.28-Adj EPS $1.32 >ABT

2025-07-17 11:32; UTC

Uždarbis

Abbott Labs: See Momentum Carrying Into 2026 >ABT

2025-07-17 11:31; UTC

Uždarbis

Abbott Labs Sees 2025 Organic Sales Up 7.5%-8%, Excluding Covid-19 Testing-Related Sales >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Organic Sales Rose 6.9% >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Adjusted Operating Margin 22.9% >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Adjusted Gross Margin 57% >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Organic Sales Growth Up 6.9% >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Sales $11.14B >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Net $1.78B >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q Adj EPS $1.26 >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs Sees FY Adj EPS $5.10-Adj EPS $5.20 >ABT

2025-07-17 11:30; UTC

Uždarbis

Abbott Labs 2Q EPS $1.01 >ABT

Akcijų palyginimas

Kainos pokytis

Abbott Laboratories Prognozė

Kainos tikslas

By TipRanks

16.46% į viršų

12 mėnesių prognozė

Vidutinis 147.13 USD  16.46%

Aukščiausias 162 USD

Žemiausias 136 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Abbott Laboratories kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

19 ratings

17

Pirkti

2

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

132.82 / 134.43Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Neutral Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

114 / 371 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
help-icon Live chat